TOP > 外国特許検索 > PREDICTION OF HEPATOCELLULAR CARCINOMA ONSET AFTER CLEARANCE OF HEPATITIS C VIRUS

PREDICTION OF HEPATOCELLULAR CARCINOMA ONSET AFTER CLEARANCE OF HEPATITIS C VIRUS

外国特許コード F180009470
整理番号 S2016-0625-C0
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP013525
国際公開番号 WO 2017191720
国際出願日 平成29年3月31日(2017.3.31)
国際公開日 平成29年11月9日(2017.11.9)
優先権データ
  • 特願2016-093483 (2016.5.6) JP
発明の名称 (英語) PREDICTION OF HEPATOCELLULAR CARCINOMA ONSET AFTER CLEARANCE OF HEPATITIS C VIRUS
発明の概要(英語) The present invention addresses the problem of providing a predictive marker useful for carcinogenesis surveillance after hepatitis C viral clearance. Provided is a predictive marker comprising a single-nucleotide polymorphism specified by rs17047200. In the present invention, the abovementioned single-nucleotide polymorphism is detected in a nucleic acid specimen collected from a subject, and the risk of hepatocellular carcinoma onset after hepatitis C viral clearance is examined.
従来技術、競合技術の概要(英語) BACKGROUND ART
C (HCV) chronic infection by the hepatitis virus, and the progress of liver fibrosis, 20-30 through the course of a year, cirrhosis, to the hepatocellular carcinoma. World level, liver cirrhosis, HCV infection of hepatocellular carcinoma is 30% and due to the weak, the number of deaths of about 2010 years and 50 million people have been reported (Non-Patent Document 1). HCV also in the United States associated with cirrhosis, hepatocellular carcinoma is 2020 years, 2022 years is to increase the number of deaths being expected to be (non-patent document 2). In recent years, a dramatic HCV infection by the treatment method, has been conventionally used a direct acting antiviral interferon is not used by a combination of a, response rate is greater than 90%, even in patients with cirrhosis was refractory to have a therapeutic effect is obtained equivalent to the (non-patent document 3). However, the treatment can eliminate HCV, carcinogenic risk is not lost completely, eliminate HCV 5 years after the primary ratio is 2.3-8.8% and the accumulation has been reported (Non-Patent Document 4). Therefore, high response rate is obtained by an anti-viral agent in the future, the primary prevention after eliminating HCV, surveillance is a very important problem.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA CITY UNIVERSITY
  • 発明者(英語)
  • TANAKA Yasuhito
  • MATSUURA Kentaro
国際特許分類(IPC)
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close